Steven H. Collis Sells 14,579 Shares of Cencora, Inc. (NYSE:COR) Stock

Cencora, Inc. (NYSE:COR - Get Free Report) Chairman Steven H. Collis sold 14,579 shares of the business's stock in a transaction that occurred on Tuesday, June 24th. The shares were sold at an average price of $292.62, for a total value of $4,266,106.98. Following the completion of the sale, the chairman now directly owns 311,913 shares in the company, valued at approximately $91,271,982.06. The trade was a 4.47% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link.

Cencora Stock Up 1.5%

Shares of Cencora stock traded up $4.38 during trading on Thursday, hitting $296.70. 1,645,496 shares of the stock were exchanged, compared to its average volume of 1,517,030. The company has a debt-to-equity ratio of 6.01, a current ratio of 0.87 and a quick ratio of 0.52. The firm's 50-day moving average price is $289.70 and its 200 day moving average price is $264.56. The stock has a market cap of $57.51 billion, a price-to-earnings ratio of 34.42, a price-to-earnings-growth ratio of 1.46 and a beta of 0.58. Cencora, Inc. has a 12-month low of $218.65 and a 12-month high of $309.35.

Cencora (NYSE:COR - Get Free Report) last announced its quarterly earnings results on Wednesday, May 7th. The company reported $4.42 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $4.07 by $0.35. Cencora had a return on equity of 344.71% and a net margin of 0.55%. The company had revenue of $75.50 billion during the quarter, compared to the consensus estimate of $75.41 billion. During the same period in the previous year, the business earned $3.80 EPS. Cencora's revenue for the quarter was up 10.3% on a year-over-year basis. As a group, analysts forecast that Cencora, Inc. will post 15.37 earnings per share for the current fiscal year.

Cencora Dividend Announcement

The firm also recently declared a quarterly dividend, which was paid on Monday, June 2nd. Investors of record on Friday, May 16th were issued a $0.55 dividend. This represents a $2.20 dividend on an annualized basis and a yield of 0.74%. The ex-dividend date of this dividend was Friday, May 16th. Cencora's dividend payout ratio (DPR) is 25.52%.

Hedge Funds Weigh In On Cencora

Several hedge funds have recently added to or reduced their stakes in COR. Net Worth Advisory Group grew its position in shares of Cencora by 1.4% in the 1st quarter. Net Worth Advisory Group now owns 2,645 shares of the company's stock valued at $736,000 after buying an additional 36 shares during the last quarter. Obermeyer Wealth Partners boosted its stake in Cencora by 1.3% in the first quarter. Obermeyer Wealth Partners now owns 2,724 shares of the company's stock valued at $758,000 after acquiring an additional 36 shares in the last quarter. Cromwell Holdings LLC boosted its stake in Cencora by 9.5% in the first quarter. Cromwell Holdings LLC now owns 450 shares of the company's stock valued at $125,000 after acquiring an additional 39 shares in the last quarter. Pinnacle Wealth Management Advisory Group LLC grew its holdings in shares of Cencora by 2.7% during the first quarter. Pinnacle Wealth Management Advisory Group LLC now owns 1,565 shares of the company's stock worth $435,000 after purchasing an additional 41 shares during the last quarter. Finally, Whittier Trust Co. increased its position in shares of Cencora by 0.6% during the fourth quarter. Whittier Trust Co. now owns 7,856 shares of the company's stock worth $1,765,000 after purchasing an additional 44 shares in the last quarter. 97.52% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Ratings Changes

Several equities analysts have weighed in on COR shares. Wall Street Zen raised Cencora from a "hold" rating to a "buy" rating in a research report on Wednesday, March 12th. Robert W. Baird lifted their price objective on shares of Cencora from $314.00 to $350.00 and gave the company an "outperform" rating in a report on Thursday, May 8th. Morgan Stanley set a $288.00 target price on shares of Cencora in a research note on Tuesday, April 15th. Citigroup raised their price target on shares of Cencora from $330.00 to $355.00 and gave the company a "buy" rating in a research report on Thursday, May 8th. Finally, Bank of America upped their price objective on Cencora from $270.00 to $285.00 and gave the stock a "neutral" rating in a research report on Friday, April 11th. One investment analyst has rated the stock with a hold rating and ten have given a buy rating to the company's stock. According to data from MarketBeat, the company currently has an average rating of "Moderate Buy" and a consensus price target of $306.91.

Cencora Company Profile

Cencora, Inc sources and distributes pharmaceutical products. The company's U.S. Healthcare Solutions segment distributes pharmaceuticals, over-the-counter healthcare products, home healthcare supplies and equipment, and related services to acute care hospitals and health systems, independent and chain retail pharmacies, mail order pharmacies, medical clinics, long-term care and alternate site pharmacies, and other customers; provides pharmacy management, staffing, and other consulting services; supply management software to retail and institutional healthcare providers; packaging solutions to various institutional and retail healthcare providers; clinical trial support, product post-approval, and commercialization support services; data analytics, outcomes research, and additional services for biotechnology and pharmaceutical manufacturers; pharmaceuticals, vaccines, parasiticides, diagnostics, micro feed ingredients, and other products to the companion animal and production animal markets; and sales force services to manufacturers.